EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Substrate‐Selective Inhibition of the SARS‐CoV‐2 Papain‐Like Protease: Inhibition of Hydrolysis of Human Over Viral Substrates

Sakshi Sharma iD, Peter A C Wing iD, Wojtek Treyde iD, Shyam Basak iD, Simeon D Draganov, Taylah Andrews-Clark, Eidarus Salah, Petra Lukacik, Claire Strain-Damerell, Adán Pinto-Fernández, Martin A Walsh iD, Fernanda Duarte und 2 weitere

Chemistry – A European Journal · 2026

DOI: 10.1002/chem.71248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry – A European Journal, 2026. Verfasst von Sakshi Sharma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Research Laboratory and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus Papain-Like Proteases, Coronavirus 3C Proteases, Protease Inhibitors. Die Arbeit nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Engineering and Physical Sciences Research Council (EPSRC), Biotechnology and Biological Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The SARS‐CoV‐2 papain‐like protease (PL pro ) and the main protease (M pro ) catalyze hydrolysis of the viral polyproteins pp1a/1ab into functional nonstructural proteins. PL pro and M pro are medicinal chemistry targets, with M pro inhibitors being used for COVID‐19 treatment. PL pro also catalyzes hydrolysis of ubiquitin and interferon‐stimulated gene 15 (ISG15) from post‐translationally modified human proteins. Here we report how screening of reported deubiquitinase inhibitors using solid‐phase extraction coupled to mass spectrometry assays with oligopeptide substrates based on pp1a/1ab and on an ISG15‐modified human protein enabled the identification of substrate‐selective PL pro inhibitors. The results reveal that the deubiquitinase inhibitor ML364 selectively inhibits the deISGylase activity of isolated PL pro over its pp1a/1ab‐processing activity. Structure‐activity relationship and computational studies support the assignment of ML364 and derivatives as substrate‐selective PL pro inhibitors. The combined results provide proof‐of‐concept for developing substrate‐selective inhibitors of PL pro and, by implication, related proteolytic enzymes, including deubiquitinases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Coronavirus Papain-Like ProteasesCoronavirus 3C ProteasesProtease InhibitorsHumansHydrolysisSubstrate SpecificityStructure-Activity RelationshipUbiquitinsUbiquitinCytokines

Stichwörter der Autor:innen

SARS‐CoV‐2 main protease / MproSARS‐CoV‐2 papain‐like protease / PLprodeubiquitinase / DUBinterferon‐stimulated gene 15 / ISG15mass spectrometryprotease inhibitionsubstrate‐selective inhibitionubiquitinvirus‐host interactions

Substanzen

papain-like protease, SARS-CoV-2ISG15 protein, humanUbiquitinsCoronavirus Papain-Like ProteasesCoronavirus 3C ProteasesUbiquitinCytokinesProtease Inhibitors

Autor:innen und Institutionen

  • Chemistry Research Laboratory and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK.
  • Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
  • Harwell Science and Innovation Campus, Diamond Light Source Ltd., Didcot, UK.
  • Harwell Science and Innovation Campus, Research Complex at Harwell, Didcot, UK.
  • Centre for Chemical Biology, Institute of Physical Chemistry, Polish Academy of Sciences, Warsaw, Poland.

ORCID-Profile: Sakshi Sharma, Peter A C Wing, Wojtek Treyde, Shyam Basak, Martin A Walsh, Christopher J Schofield

Förderung

  • Cancer Research UK
  • Engineering and Physical Sciences Research Council (EPSRC)
  • Biotechnology and Biological Sciences Research Council
  • Wellcome Trust
  • Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China

Zitieren

APA

Sharma, S., Wing, P. A. C., Treyde, W., Basak, S., Draganov, S. D., Andrews-Clark, T., Salah, E., Lukacik, P., Strain-Damerell, C., Pinto-Fernández, A., Walsh, M. A., Duarte, F., Schofield, C. J., & Brewitz, L. (2026). Substrate‐Selective Inhibition of the SARS‐CoV‐2 Papain‐Like Protease: Inhibition of Hydrolysis of Human Over Viral Substrates. Chemistry – A European Journal. https://doi.org/10.1002/chem.71248

Vancouver

Sharma S, Wing PAC, Treyde W, Basak S, Draganov SD, Andrews-Clark T, et al. Substrate‐Selective Inhibition of the SARS‐CoV‐2 Papain‐Like Protease: Inhibition of Hydrolysis of Human Over Viral Substrates. Chemistry – A European Journal. 2026. doi:10.1002/chem.71248

BibTeX
@article{Sharma2026,
  author = {Sharma, Sakshi and Wing, Peter A C and Treyde, Wojtek and Basak, Shyam and Draganov, Simeon D and Andrews-Clark, Taylah and Salah, Eidarus and Lukacik, Petra and Strain-Damerell, Claire and Pinto-Fernández, Adán and Walsh, Martin A and Duarte, Fernanda and Schofield, Christopher J and Brewitz, Lennart},
  title = {Substrate‐Selective Inhibition of the SARS‐CoV‐2 Papain‐Like Protease: Inhibition of Hydrolysis of Human Over Viral Substrates},
  journal = {Chemistry – A European Journal},
  year = {2026},
  doi = {10.1002/chem.71248}
}
Kostenlos starten →